Hence, targeting enzymes involved in SL metabolism, such as SMPDL3b, SPHKs, acid ceramidases and glycosphingolipid synthases, targeting SL metabolites such as ceramides, S1P, C1P, GM3 and Gb3, or targeting S1P receptors could be potential new avenues to develop new therapeutic agents for the treatment of patients with renal diseases. This evidence concerns the gene ASAH1 and kidney disorder.